Mahmud Md Kayes, Jalil Shahnaz, Rahman Ahm Mahmudur, Rashid Md Mamun-Ur, Sultana Shiny, Taher Adnan, Haque Lutful, Fardous Jannatul, Nahar Kamrun
Department of Pharmaceutical Sciences, North South University, Dhaka, Bangladesh.
Department of Pharmacy, Comilla University, Comilla, Bangladesh.
Avicenna J Med. 2017 Jul-Sep;7(3):125-129. doi: 10.4103/ajm.AJM_161_16.
The endeavor of the study was to analyze the posttreatment (postradioactive iodine therapy [RAI]) conditions of thyrotoxic patients in a tertiary level hospital.
A retrospective study of 186 patients was conducted from 2012 to 2014 in Institute of Nuclear Medicine and Allied Sciences (INMAS), Sylhet MAG Osmani Medical College Campus. Patients' information regarding the etiologies and their disease status after getting RAI therapy was recorded.
In this study, 29.57% patients were male and 70.43% were female where the mean ages were 44.57 and 43.46 accordingly. The most vulnerable group was in between 41 and 50 years of age, which is 25.81%. The patients were categorized according to the etiologies as Graves' disease (GD), multinodular goiter (MNG), and single toxic nodule (STN). In primary stage, 60.22% patients had GD, 26.88% had MNG, and 12.90% had STN. After 6 months of RAI therapy, the disease status of 51.61% patients became euthyroid, 19.35% became hypothyroid, and 29.03% remained thyrotoxic. Thus, a second dose of RAI therapy was given to those patients for next 6 months. After 12 months from the beginning of the therapy of each patient, the total recovery was found to be 72.04%. However, though all the GD patients improved to either euthyroid or hypothyroid state after 6 months, on a 12-month observation, 17.86% of them regained the thyrotoxicosis due to discontinuation of the treatment.
The findings show an overall significant recovery of thyrotoxic patients taking RAI therapy in INMAS and important points to improve the rate.
本研究旨在分析一家三级医院中甲状腺毒症患者的治疗后(放射性碘治疗 [RAI] 后)情况。
2012年至2014年在锡尔赫特MAG奥斯曼尼医学院校区核医学与相关科学研究所(INMAS)对186例患者进行了回顾性研究。记录了患者的病因信息及其接受RAI治疗后的疾病状态。
在本研究中,男性患者占29.57%,女性患者占70.43%,相应的平均年龄分别为44.57岁和43.46岁。最易患病的年龄组在41至50岁之间,占25.81%。患者根据病因分为格雷夫斯病(GD)、多结节性甲状腺肿(MNG)和单发性毒性结节(STN)。在初始阶段,60.22%的患者患有GD,26.88%患有MNG,12.90%患有STN。RAI治疗6个月后,51.61%的患者病情变为甲状腺功能正常,19.35%变为甲状腺功能减退,29.03%仍为甲状腺毒症。因此,在接下来的6个月里,对这些患者给予了第二剂RAI治疗。从每位患者开始治疗12个月后,总康复率为72.04%。然而,尽管所有GD患者在6个月后病情改善为甲状腺功能正常或减退状态,但在12个月的观察中,其中17.86%的患者因停止治疗而再次出现甲状腺毒症。
研究结果表明,在INMAS接受RAI治疗的甲状腺毒症患者总体上有显著康复,且有重要要点可提高康复率。